Diagnostic method for disorders using copeptin
AssigneeB.R.A.H.M.S GmbH
InventorsAndreas BERGMANN, Joachim STRUCK
Life of this patent
Estimating the term…
Abstract
The use of copeptin as diagnostic marker for the determination of the release of vasopressin, especially in connection with disorders associated with non-physiological alterations of vasopressin release from the neurohypophysis, especially for detection and early detection, diagnosing and monitoring of the course of cardiovascular diseases, renal and pulmonary diseases as well as shock, including septic shock, sepsis and diseases/disorders of the central nervous system and neurodegenerative diseases.
Claims17
A diagnostic in vitro method for the diagnosis and monitoring of disorders associated with or caused by non-physiological alterations of vasopressin release from the neurohypophysis by determining in a sample of a body fluid of the patient the amount of copeptin and/or a pathophysiologically occurring precursor, splice variant, fragment or posttranslationally modified form of copeptin displaying copeptin immunoreactivity, and associating the determined amount of copeptin or copeptin immunoreactivity with the presence and/or course and/or severity and/or prognosis of such disorder.
9-12. (canceled)
A method for the diagnosis of a disorder associated with or caused by abnormal alterations of vasopressin release from the neurohypophysis, said method comprising:
- (a) obtaining a sample of a bodily fluid from a patient;
- (b) contacting said sample with (i) a first antibody that specifically binds a first epitope on a first peptide consisting of amino acids 132-147 of SEQ ID NO.:
- 4, and (ii) a second antibody that specifically binds a second epitope on a second peptide consisting of amino acids 149-164 of SEQ ID NO.:
- 4;
- wherein at least one of said first and second antibodies comprises a detectable label;
- (c) determining the level of detectable label in said sample, wherein the amount of detectable label correlates to the level of copeptin, wherein an increase in the level of copeptin in said sample as compared to the level in healthy individuals indicates the disorder.
A method for the diagnosis of a disorder associated with or caused by abnormal alterations of vasopressin release from the neurohypophysis, said method comprising:
- (a) obtaining a sample of a bodily fluid from a patient;
- (b) contacting said sample with (i) a first antibody that specifically binds a first epitope within amino acids 132-147 of SEQ ID NO.:
- 4, and (ii) a second antibody that specifically binds a second epitope within amino acids 149-164 of SEQ ID NO.:
- 4;
- wherein at least one of said first and second antibodies comprises a detectable label;
- (c) determining the level of detectable label in said sample, wherein the amount of detectable label correlates to the level of copeptin, wherein an increase in the level of copeptin in said sample as compared to the level in healthy individuals indicates the disorder.
Dependencies are inferred from the claim text.